# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-068602
Filing Date
2025-05-12
Accepted
2025-05-12 08:19:03
Documents
79
Period of Report
2025-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | mbx-20250331.htm iXBRL | 10-Q | 1574649
2 | EX-10.1 | mbx-ex10_1.htm | EX-10.1 | 121464
3 | EX-31.1 | mbx-ex31_1.htm | EX-31.1 | 17255
4 | EX-31.2 | mbx-ex31_2.htm | EX-31.2 | 17383
5 | EX-32.1 | mbx-ex32_1.htm | EX-32.1 | 16633
| Complete submission text file | 0000950170-25-068602.txt |  | 7487561

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | mbx-20250331.xsd | EX-101.SCH | 1119578
82 | EXTRACTED XBRL INSTANCE DOCUMENT | mbx-20250331_htm.xml | XML | 1293669

Mailing Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032
Business Address 11711 N. MERIDIAN STREET SUITE 300 CARMEL IN 46032 3179893100
MBX Biosciences, Inc. (Filer) CIK: 0001776111 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42272 | Film No.: 25932713
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)